C12N 2770/36234
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/36234 (Use of virus or viral component as vaccine) appears on 31 US grants and 34 published applications in this corpus.
Search patents in C12N- Granted patents
- 31
- Published applications
- 34
- Assignees
- 29
- Inventors
- 93
- Latest grant
- 22 Apr 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 3 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 3 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 2 |
| 2004 | 2 | 2 |
| 2005 | 1 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 2 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 1 | 1 |
| 2014 | 1 | 2 |
| 2015 | 0 | 3 |
| 2016 | 0 | 3 |
| 2017 | 1 | 3 |
| 2018 | 3 | 2 |
| 2019 | 4 | 2 |
| 2020 | 0 | 0 |
| 2021 | 1 | 1 |
| 2022 | 1 | 2 |
| 2023 | 1 | 1 |
| 2024 | 1 | 1 |
| 2025 | 1 | 5 |
By publication year. Applications have been published since 2001.
Recent patents
- Compositions and methods for stabilization of active agents22 Apr 2025US 12,280,101 B2Trustees of Tufts College
- Identifying patient populations vulnerable to viral infection and methods of inducing heterologous immunity in same26 Mar 2024US 11,938,181 B2nference, Inc.
- Rubella virus spike construct10 Oct 2023US 11,780,884 B2Institut Virion \ Serion GmbH
- Multiple viral antigen COVID vaccine and therapeutic8 Nov 2022US 11,491,197 B2
- Methods and compositions for therapeutic agents9 Nov 2021US 11,167,032 B2Variation Biotechnologies Inc.
- Vaccine composition or kit for reducing size or volume of target tissue, containing genetic material that encodes foreign antigen30 Oct 2025US 2025/0332250 A1SK Bioscience Co., Ltd.
- Composition for reducing size or volume of target tissue or kit including same4 Sep 2025US 2025/0276028 A1SK Bioscience Co., Ltd.
- Melting Microneedle Patches and Methods of Manufacturing Thereof29 May 2025US 2025/0170379 A1Georgia Tech Research Corporation
- Signal sequences for nucleic acid vaccines22 May 2025US 2025/0161425 A1Sanofi
- Freeze-dried viral combination vaccine compositions and process for preparation thereof20 Feb 2025US 2025/0057939 A1Codagenix Inc.
Most cited
By later US patents
- Materials and methods for treatment of plaquing diseases96US 5,851,996 AMilkhaus Laboratory, Inc. · 1998
- Materials and methods for treatment of plaquing disease92US 5,753,624 AMilkhaus Laboratory, Inc. · 1998
- Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell40US 6,825,036 B2Juridical Foundation The Chemo-Sero-Therapeutic Research Institute · 2004
- Production of viruses in tissue culture without use of serum39US 4,072,565 AThe Dow Chemical Company · 1978
- Stabilizers for live vaccines25US 6,231,860 B1Pasteur Merieux Serums & Vaccins · 2001